产品描述 概述Recombinant Human Coagulation Factor IX is produced by our Mammalian expression system and the target gene encoding Thr29-Thr461 is expressed with a 6His tag at the C-terminus. 使用说明This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. 技术规格| Tag | C-6His | | 种属 | Human | | 表达系统 | Human cells | | Accession# | P00740 | | Source | Human Cells | | Formulation_Description | Supplied as a 0.2 μm filtered solution of 20mM TrisHCl, 150mM NaCl, 10% Glycerol, pH 8.0. | | Storage | Store at < -20°C, stable for 6 months after receipt.Please minimize freeze-thaw cycles. | | Purity | Greater than 95% as determined by reducing SDS-PAGE. | | Endotoxin | Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. | | Background | Coagulation factor IX（F9), is a member of the peptidase S1 family. It contains two EGF-like domains, a Gla domain and a peptidase S1 domain. It is primarily expressed in the liver and secreted in plasma. Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa. Mutations in position 43 and 46 prevents cleavage of the propeptide, mutation in position 93 probably fails to bind to cell membranes, mutation in position 191 or in position 226 prevent cleavage of the activation peptide. Mutations of human F9 can result in thrombophilia and recessive X-linked hemophilia B (HEMB). An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. |
|
